Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2014, Article ID 536856, 5 pages
Case Report

Effectiveness and Safety of Infliximab in Two Cases of Severe Chondrocalcinosis: Nine Years of Follow-Up

1SEEBMO, Hospital de Santo Espírito da Ilha Terceira, 9700 Angra do Heroísmo, Portugal
2Genetics & Arthritis Research Group (GARG), Institute for Molecular and Cell Biology (IBMC), 4150 Oporto, Portugal
3Grupo de Epidemiologia e Genética Humana do Departamento de Biologia da Universidade dos Açores, 9500 Ponta Delgada, Portugal
4Rheumatology Research Unit, Molecular Medicine Institute, Lisbon, Portugal
5Serviço de Medicina Interna, Hospital de Santo Espírito da Ilha Terceira, 9700 Angra do Heroísmo, Portugal
6Merck Sharp & Dohme, 1135 Brussels, Belgium
7University of Queensland, Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, Brisbane, QLD 4192, Australia

Received 12 August 2014; Accepted 14 October 2014; Published 11 November 2014

Academic Editor: Mario Salazar-Paramo

Copyright © 2014 Jácome Bruges-Armas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objectives. To investigate the efficacy of infliximab in the treatment of severe calcium pyrophosphate deposition diseases (CPPD). Methods. Two patients with severe CPPD and diffuse idiopathic skeletal hyperostosis- (DISH-) like phenotype are described. Both patients were resistant to therapy with nonsteroidal anti-inflammatory drugs (NSAIDs). Both patients were treated with infliximab, a TNF-α receptor antagonist, for nine years. Results. Treatment with infliximab resulted in major clinical and laboratory improvements without relevant side effects. Conclusions. These results suggest that infliximab may be an effective treatment of severe CPDD.